Noticias y vídeos - AURIS MEDICAL HOLDING - Página 2

Up to 99.4% reduction of viral titer in human epithelial cell culture (p<0.001) Results suggest potential for AM-301 nasal spray to mitigate risk of Sars-CoV-2 infection Hamilton, Bermuda, December 1, 2020 – Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology, rhinology and allergy and CNS disorders, today announced positive efficacy data from testing AM-301 in vitro . AM-301 is a...

Hamilton, Bermuda, November 20, 2020 – Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology, rhinology and allergy and CNS disorders, today announced the launch of a dedicated website for its affiliate Altamira Medica Ltd. The website, www.altamiramedica.com , offers quick and easy access to information about the Company’s development of AM-301, a drug-free nasal spray intended for...

Hamilton, Bermuda, October 13, 2020 – Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology and central nervous system disorders, today announced that the first patient has been randomized in Part B of its “TRAVERS” Phase 2 trial of AM-125 (intranasal betahistine) in acute vertigo. This follows the positive read-out from the interim analysis on Part A of the study in early September...

Auris Medical is a biopharmaceutical company dedicated to developing therapeutics that address important unmet medical needs in neurotology and central ......

Advancing Phase 2 trial with AM-125 in acute vertigo based on positive interim data Positive outcome from AM-201 trial in prevention of antipsychotic-induced weight gain Addition of new intranasal program with development of drug-free spray for protection against airborne pathogens and allergens Review of strategic options initiated Hamilton, Bermuda, September 17, 2020 – Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address...

Hamilton, Bermuda, September 11, 2020 – Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology and central nervous system disorders, today announced that it will provide a business update and report its financial results for the first half 2020 on Thursday, September 17, 2020. Following the announcement, Auris Medical's management team will host a live conference call and webcast at 8:30...

Development of AM-301 nasal spray initiated with aim of regulatory submission in 2021 Key component of AM-301 shown to reduce SARS-CoV-2 viral infectious load in vitro by up to 99% Creation of dedicated subsidiary, Altamira Medica Ltd, to focus solely on AM-301 development program CHF 1.5 m convertible loan arranged in support of development program Hamilton, Bermuda, September 8, 2020 – Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics...

Dose dependent improvement in balance tests over placebo in Part A of TRAVERS trial Improvement 1.9 to 2.4 times greater with highest dose than with placebo Trial to proceed with Part B to test AM-125 10 and 20 mg vs. placebo Hamilton, Bermuda, September 3, 2020 – Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology and central nervous system disorders, today announced positive...

Hamilton, Bermuda, August 20, 2020 – Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology and central nervous system disorders, today announced that it has regained compliance with the Nasdaq listing requirements. On August 20, 2020, the Company received a letter from Nasdaq stating that because the Company’s shares had a closing bid price at or above $1.00 per share for a minimum of...

Dose escalation completed as last patient enrolled into Part A of TRAVERS study Interim results to be announced in Q3 of 2020 Hamilton, Bermuda, July 29, 2020 – Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology and central nervous system disorders, today announced the completion of patient enrollment into Part A of its Phase 2 “TRAVERS” trial with intranasal betahistine in...

Administration of intranasal betahistine 30 mg shows statistically significant reduction in olanzapine-induced weight gain Treatment well tolerated and safe with no adverse effects Enrollment into Phase 2 TRAVERS trial with AM-125 resumed following break due to COVID-19 pandemic Hamilton, Bermuda, May 26, 2020 – Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology and central nervous...

Phase 1b trial with intranasal betahistine for prevention of antipsychotic-induced weight gain progressing towards final read-out Phase 2 trial with intranasal betahistine for treatment of acute vertigo progressing towards interim analysis, but temporarily slowed down by COVID-19 impact Notice of allowance granted for NKCC1 modulators for oral treatment of tinnitus Set-up of subsidiary to bundle tinnitus and hearing loss development projects for potential partnering Hamilton, Bermuda, April 16,...

Phase 1b trial with AM-201 proceeding as planned to data read-out in early May 2020 Enrollment into Phase 2 trial with AM-125 impacted by COVID-19 pandemic Company to report 2019 second-half and full year results and provide general business update on April 16, 2020 Hamilton, Bermuda, April 3, 2020 – Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology and central nervous system...

Last subject had last treatment visit in Phase 1b trial with AM-201 in prevention of antipsychotic-induced weight gain and somnolence; data read-out expected for early May 2020 Phase 2 trial with AM-125 in treatment of acute peripheral vertigo progressing towards interim analysis in Q2 2020 Hamilton, Bermuda, March 5, 2020 – Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology and...

Hamilton, Bermuda, February 25, 2020 - Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology and central nervous system disorders, today highlighted the publication of an article describing the anti-epileptic and anti-convulsive activity of betahistine in a mouse model. The peer-reviewed article titled “Betahistine prevents kindling, ameliorates the behavioral comorbidities and...

Received “Intention to Grant” notice from European Patent Office Application covers invention of oral treatment for tinnitus Hamilton, Bermuda, January 10, 2020 – Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology and central nervous system disorders, today announced that the European Patent Office (EPO) has issued a notice of “Intention to Grant” for its patent application...

...

Hamilton, Bermuda, Dec. 30, 2019 (GLOBE NEWSWIRE) -- Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology and central nervous system disorders, today announced the formation of a new subsidiary, Zilentin Ltd., to bundle its development projects for the treatment of tinnitus and hearing loss in a separate entity. Upon completion of the transfers from other Group companies, Zilentin AG...

Hamilton, Bermuda, Oct. 11, 2019 (GLOBE NEWSWIRE) -- Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology and central nervous system disorders, today announced positive interim results from its Phase 1b trial with AM-201 in antipsychotic-induced weight gain and somnolence. The study demonstrated good safety and tolerability of AM-201 over the four-week treatment period and revealed...

Hamilton, Bermuda, Sept. 13, 2019 (GLOBE NEWSWIRE) -- Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology and central nervous system disorders, today announced that it has obtained advice on the development plan and regulatory pathway for its investigational tinnitus treatment Keyzilen ® (AM-101) from the U.S. Food and Drug Administration (“FDA”) and from the European Medicines...